FAIRFAX, VA / ACCESSWIRE / September 28, 2022 / WidePoint Corporation (NYSE American:WYY) , the Trusted Mobility Solutions company, announced that WidePoint IAM Solutions is now being piloted within IT groups at several K-12 schools. The Phase 1 Pilot project includes the elimination of user name and password for Tier 1 IT staff for system and network access, for securing email communication with the schools, and for controlling physical access using existing door readers. Phase 2 will include all school staff members, and scheduling the other phases. Jason Holloway, WidePoint''s Chief Revenue Officer, stated: "Ransomware attacks on our nation''s school districts and systems are creating a strain on students, staff and resources, draining technology funding, devastating budgets and impacting technology investments that can benefit students and secure schools. Frankly, many of the security offerings in place are not working." The WidePoint-ORC cybersecurity team pioneered Public Key Infrastructure (PKI) with the U.S.
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell samples in a single automated workflow, including cell identity, quality and quantity. The cutting-edge Cellaca PLX system, designed by the company’s Nexcelom unit, combines best-in-class im
PerkinElmer with ticker code (PKI) now have 12 analysts in total covering the stock. The consensus rating is ''Hold''. The target price ranges between 202 and 140 with the average target price sitting at 172.42. Now with the previous closing price of 125.95 this would indicate that there is a potential upside of 36.9%. There is a 50 day moving average of 143.05 while the 200 day moving average is 160.24. The company has a market cap of $15,555m. Visit the company website at: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $21,294m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
Major players in the microfluidics market are Illumina, Inc. , PerkinElmer, Inc. , Agilent Technologies, Inc. , Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Elveflow, Cellix Ltd. , Fluidigm Corporation, Fluigent SA, Zeon Corporation, Innovative Biochips, LLC, Dolomite Microfluidics, Idex Corporation, and UFluidix. Major players in the microfluidics market are Illumina, Inc. , PerkinElmer, Inc. , Agilent Technologies, Inc. , Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Elveflow, Cellix Ltd. , Fluidigm Corporation, Fluigent SA, Zeon Corporation, Innovative Biochips, LLC, Dolomite Microfluidics, Idex Corporation, and UFluidix.
PerkinElmer''s (PKI) Oxford Immunotec said that the U.S
Major players in the epigenetics market are Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode, Hoffmann-La Roche Ltd, Eisai Co Ltd and Novartis AG. Major players in the epigenetics market are Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, Active Motif, Bio-Rad, New England Biolabs, Agilent, Qiagen, Zymo Research, Perkinelmer, Diagenode, Hoffmann-La Roche Ltd, Eisai Co Ltd and Novartis AG.
PerkinElmer, Inc. (NYSE:NYSE:PKI) Baird’s 2022 Global Healthcare Conference September 13, 2022 10:50 AM ET Company Participants Prahlad Singh - CEO Conference Call Participants Tom Peterson…
Major players in the environmental testing equipment market are Agilent Technologies Inc, Thermo Fisher Scientific Inc, Shimadzu Corporation, Waters Corporation, Bruker Corporation, PerkinElmer Inc, Merck KGaA, Teledyne Technologies Incorporated, INFICON, JEOL Ltd, SCIEX, Extech Instruments, Amphenol, and PathSensors, Inc. Major players in the environmental testing equipment market are Agilent Technologies Inc, Thermo Fisher Scientific Inc, Shimadzu Corporation, Waters Corporation, Bruker Corporation, PerkinElmer Inc, Merck KGaA, Teledyne Technologies Incorporated, INFICON, JEOL Ltd, SCIEX, Extech Instruments, Amphenol, and PathSensors, Inc.
Digital Pathology Market 2022-2028 New Jersey, NJ -- ( SBWIRE ) -- 09/12/2022 -- The Latest research study released by HTF MI "Global Digital Pathology Market" with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered in this Research are Danaher, Hamamatsu Photonics, Roche, Philips, Olympus, PerkinElmer, Sectra, Nikon, Definiens, 3DHISTECH, Visiopharm, Apollo Enterprise Imaging, Glencoe Software, Indica Labs, OptraSCAN, Objective Pathology, Digipath, Pathcore, Mikroscan Technologies, Inspirata, Huron Digital Pathology, ContextVision etc. Click here for free sample + related graphs of the report @: https://www.htfmarketreport.com/sample-report/4025944-2022-2030-report-on-global-digital-pathology-market Browse market information, tables and figures extent in-depth TOC on "Digital Pathology Market by Application ( Pharma & Biotech Companies, Hospital & Diagnostic Centers, Educational Institutes), by Product Type (, Whole Slide Imaging, Image Analysis-Informatics, Information Management System Storage & Communication, Digital IVD Devices, Others), Business scope, Manufacturing and Outlook – Estimate to 2027". for more information or any query mail at sales@htfmarketreport.com At last, all parts of the Global Digital Pathology Market are quantitatively also subjectively valued to think about the Global just as regional market equally.
Major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc. , Abcam plc, Bio-Rad Laboratories, Inc. , PerkinElmer Inc. , Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc. Major players in the immunofluorescence assay market are Thermo Fisher Scientific, Inc. , Abcam plc, Bio-Rad Laboratories, Inc. , PerkinElmer Inc. , Werfen Company, Merck KGaA, Agilent Technologies, Becton Dickinson and Company, Maxvision Biosciences Inc.
PerkinElmer with ticker code (PKI) have now 12 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The range between the high target price and low target price is between 202 and 149 with the average target price sitting at 173.17. With the stocks previous close at 134.65 this indicates there is a potential upside of 28.6%. The day 50 moving average is 145.33 while the 200 day moving average is 162.97. The market capitalisation for the company is $17,497m. Visit the company website at: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $22,503m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
PerkinElmer sold a substantial business in recent times, in order to fully focus on life science and diagnostic activities. See why I''m adding PKI to my position.
PerkinElmer found using ticker (PKI) have now 12 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The target price ranges between 202 and 149 calculating the average target price we see 173.17. Now with the previous closing price of 141.39 this is indicating there is a potential upside of 22.5%. The 50 day moving average now sits at 146.12 and the 200 day MA is 164.86. The market cap for the company is $18,229m. You can visit the company''s website by visiting: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $22,327m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
https://www.investing.com/news/pro/stifel-downgrades-perkinelmer-to-hold-432SI-2875307
Moderna Inc (NASDAQ: MRNA ) appointed James Mock as its Chief Financial Officer, beginning September 6, 2022. In May, Moderna''s newly appointed Chief Financial Officer, Jorge Gomez, departed the company immediately after joining office a day before. The announcement follows the public disclosure by … Full story available on Benzinga.com
PerkinElmer (PKI) announced Wednesday the departure of senior vice president and chief financial officer Jamey Mock as he joins Moderna (MRNA) as its finance chief. The Board of…
Moderna Inc. said Wednesday that Chief Financial Officer David Meline will retire, effective Sept. 6. Moderna shares fell 0.6% in premarket trading. The biotechnology company, which has one of the approved COVID-19 vaccines, said it has appointed James Mock as CFO, also starting Sept. 6. Mock was most recently CFO of PerkinElmer Inc. for the past four years, after spending nearly 20 years in various financial oversight roles at General Electric Co. in the U.S. and abroad. "Jamey''s experience in scaling global businesses will ensure we continue to be well positioned for the future," said Chief Executive Stéphane Bancel. Moderna''s stock has dropped 33.9% year to date through Tuesday, while the iShares Biotechnology ETF has lost 12.9% and the S&P 500 has declined 9.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
PerkinElmer found using ticker (PKI) now have 11 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The range between the high target price and low target price is between 202 and 149 and has a mean target at 174.82. Given that the stocks previous close was at 158.26 this is indicating there is a potential upside of 10.5%. There is a 50 day moving average of 145.61 and the 200 moving average now moves to 166.16. The company has a market cap of $20,317m. Find out more information at: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $22,443m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
The global "Lab Automation Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Lab Automation market report highlight the latest development
The "Mad Money" host interviewed PerkinElmer CEO Prahlad Singh on Thursday''s episode of the show.
PerkinElmer found using ticker (PKI) now have 11 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The target price ranges between 202 and 149 calculating the average target price we see 173. Given that the stocks previous close was at 154.23 this would indicate that there is a potential upside of 12.2%. There is a 50 day moving average of 144.82 and the 200 day moving average is 166.66. The market capitalisation for the company is $19,456m. Find out more information at: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $21,824m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
PerkinElmer, Inc. (NYSE:NYSE:PKI) Q2 2022 Earnings Conference Call August 04, 2022, 08:00 ET Company Participants Stephen Willoughby - VP, IR Prahlad Singh - CEO, President & Director…
The following slide deck was published by PerkinElmer, Inc.
PerkinElmer (PKI) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.The consensus EPS Estimate is $1.44 (-49.1% Y/Y) and the consensus…
Following an earnings-led rally yesterday, the shares of life sciences company PerkinElmer, Inc
https://www.investing.com/news/pro/perkinelmer-pt-lowered-to-190-at-stifel-432SI-2860544
Stocks that traded heavily or had substantial price changes Monday: PerkinElmer, Boeing rise; Royal Caribbean, Aerojet fall
PerkinElmer to Sell Applied, Food and Enterprise Services to Private Equity Firm
PerkinElmer posted its Q2 earnings and prompted an upward revision of its FY22 guidance. Click here to know why we rate PKI stock as a speculative buy.
These are the stocks posting the largest moves in midday trading.
TGT rose on an analyst''s upgrade. ABBV fell following a downgrade. CEPH jumped on news that PEP had taken a stake in the company. PKI rose on a sale of some businesses and strong results.
New Mountain Capital to acquire PerkinElmer’s Applied, Food and Enterprise Services businesses for up to $2.45bn Submitted 01/08/2022 - 2:03pm New Mountain Capital, a growth-oriented investment firm with over $37 billion in assets under management, is to acquire PerkinElmer’s Applied, Food and Enterprise Services businesses, a carve-out from the Discovery & Analytical Solutions segment of PerkinElmer, Inc (NYSE: PKI), for up to $2.45 billion. The business being acquired includes PerkinElmer’s leading OneSource laboratory and field services, along with a portfolio of atomic spectroscopy, molecular spectroscopy, and chromatography instruments, consumables and reagents that serve the biopharma, food, environmental & safety and applied end markets. The PerkinElmer brand will be transferred with the business, and the transaction is expected to close in the first quarter of 2023, subject to regulatory approvals and other customary closing conditions. New Mountain Capital was advised by Jefferies as exclusive financial advisor and Simpson Thacher & Bartlett as lead legal counsel.
PerkinElmer with ticker code (PKI) now have 12 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 200 and 125 calculating the mean target price we have 171.25. Given that the stocks previous close was at 150.69 this would indicate that there is a potential upside of 13.6%. The 50 day MA is 143.85 and the 200 moving average now moves to 167.01. The market capitalisation for the company is $19,962m. Visit the company website at: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $22,686m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
PerkinElmer is the only diagnostics company to offer two different placental growth factor (PlGF)-based tests recommended in updated guidance PerkinElmer, Inc., a global leader committed to innova…
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a placental growth factor (PlGF) measurement using its DELFIA® Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA® Xpress sFlt-1 kit (CE-IVD), have been included in an updated diagnostic guidance issued by the United Kingdom’s National Institute for Health and Care Excellence (NICE) to help diagnose su
PerkinElmer (NYSE:PKI) declares $0.07/share quarterly dividend, in line with previous.Forward yield 0.19%Payable Nov. 11; for shareholders of record Oct. 21; ex-div Oct.
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of PerkinElmer, Inc. (NYSE: PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 11, 2022 to all shareholders of record at the close of business on October 21, 2022. About PerkinElmer PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $5 billion in 2021, has more than 16,000 employees serving cus
PerkinElmer with ticker code (PKI) now have 12 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 200 and 125 and has a mean target at 171.25. Given that the stocks previous close was at 139.92 this now indicates there is a potential upside of 22.4%. The 50 day moving average now sits at 143.44 and the 200 day MA is 167.53. The company has a market capitalisation of $18,665m. Company Website: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $22,844m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
The investment back also released an updated rating for Danaher as it expanded its coverage of the life science tools and diagnostic market.
Looking at the universe of stocks we cover at Dividend Channel, on 7/21/22, Patterson Companies Inc (Symbol: PDCO), CVS Health Corporation (Symbol: CVS), and PerkinElmer, Inc. (Symbol: PKI) will all trade ex-dividend for their respective upcoming dividends. Patterson Companies
PerkinElmer found using ticker (PKI) have now 11 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 200 and 125 calculating the mean target price we have 172.27. Now with the previous closing price of 137.09 this would indicate that there is a potential upside of 25.7%. The day 50 moving average is 144.55 and the 200 day MA is 168.4. The company has a market capitalisation of $16,863m. You can visit the company''s website by visiting: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $21,191m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
Upgrades For The Shyft Group Inc (NASDAQ: SHYF ), DA Davidson upgraded the previous rating of Neutral to Buy. Shyft Group earned $0.06 in the first quarter, compared to $0.36 in the year-ago quarter. The current stock performance of Shyft Group shows a 52-week-high of $54.50 and a 52-week-low of $17.66. Moreover, at the end of the last trading period, the closing price was at $19.28. According to Morgan Stanley, the prior rating for US Silica Holdings Inc (NYSE: SLCA ) was changed from Underweight to Equal-Weight. US Silica Holdings earned $0.02 in the first quarter, compared to $0.28 in the year-ago quarter. The current stock performance of US Silica Holdings shows a 52-week-high of $21.54 and a 52-week-low of $7.22. Moreover, at the end of the last trading period, the closing price was at $10.14. JP Morgan upgraded the previous rating for Ambev SA (NYSE: ABEV ) from Neutral to Overweight. For the first quarter, Ambev had an EPS of $0.04, compared to year-ago quarter EPS of $0.03. At the moment, the stock has a 52-week-high of $3.55 and a 52-week-low of $2.42.
Cytogenetics Software Market May See A Big Move New Jersey, NJ -- ( SBWIRE ) -- 07/05/2022 -- Latest released Cytogenetics Software Market Research Report provides detailed assessment of Key and emerging players showcasing company profiles, product/service offerings, market price, and sales revenue to better derive market size estimation. With this assesment the aim is to provide viewpoint on upcoming trends, growth drivers, opinions and facts derived from industry executives with statistically supported and market validated data. Furthermore, a detailed commentary on How or Why this market may see a growth momentum during the forecast period is analysed and correlated with dominating and emerging players strength and weakness. Whats keeping Leica Biosystems, Agilent, Applied Spectral Imaging, MetaSystems, BioView, LUCIA Cytogenetics, PerkinElmer & Cytognomix gain competitive edge in Cytogenetics Software Market and stay up-to-date with available business opportunity in various segments and emerging territory.
Upgrades For Crocs Inc (NASDAQ: CROX ), Loop Capital upgraded the previous rating of Hold to Buy. For the first quarter, Crocs had an EPS of $2.05, compared to year-ago quarter EPS of $1.49. At the moment, the stock has a 52-week-high of $183.88 and a 52-week-low of $46.08. Crocs closed at $47.95 at the end of the last trading period. According to Macquarie, the prior rating for Live Nation Entertainment Inc (NYSE: LYV ) was changed from Neutral to Outperform. Live Nation Entertainment earned $0.39 in the first quarter, compared to $1.44 in the year-ago quarter. The stock has a 52-week-high of $127.75 and a 52-week-low of $74.23. At the end of the last trading period, Live Nation Entertainment closed at $83.06. According to Wells Fargo, the prior rating for Excelerate Energy Inc (NYSE: EE ) was changed from Equal-Weight to Overweight. The stock has a 52-week-high of $30.82 and a 52-week-low of $18.40. At the end of the last trading period, Excelerate Energy closed at $19.16. For Antero Resources Corp (NYSE: AR ), Truist Securities upgraded the previous rating of Hold to Buy.
PerkinElmer with ticker code (PKI) have now 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 200 and 125 calculating the average target price we see 178.64. With the stocks previous close at 140.41 this indicates there is a potential upside of 27.2%. The 50 day MA is 150.84 and the 200 day MA is 172.62. The market capitalisation for the company is $17,350m. You can visit the company''s website by visiting: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $22,074m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
Major players in the laboratory automation systems market are Tecan Group, Perkinelmer, Thermo Fisher Scientific, Agilent Technologies, Danaher, Qiagen, Roche, Abbott, Siemens, and Eppendorf. Major players in the laboratory automation systems market are Tecan Group, Perkinelmer, Thermo Fisher Scientific, Agilent Technologies, Danaher, Qiagen, Roche, Abbott, Siemens, and Eppendorf.
New York, USA, May 26, 2022 (GLOBE NEWSWIRE) -- The Global Next-Generation Sequencing Market to register Sustainable Growth at a CAGR of 18.96% During the Study Period (2018-26), Assesses DelveInsight As per DelveInsight Analysis in the Next-Generation Sequencing market, the growing application of the Next-Generation Sequencing technology in various fields such as clinical diagnosis, scientific research, and others is projected to propel the Next-Generation Sequencing market. Additionally, the advancement in the Next-Generation Sequencing platform is likely to increase the adoption of Next-Generation Sequencing technology thereby driving Next-Generation Sequencing market growth in the forthcoming years. According to the latest report published by DelveInsight " Next Generation Sequencing Market Insight , the global Next-Generation Sequencing market is expected to witness significant growth owing to the rise in cases of infectious diseases and various other complex disorders such as cancer, genetic disorders, and others across the globe.
Major players in the live cell imaging market are Leica Microsystems, Olympus Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc, GE Healthcare, Carl Zeiss Meditec AG, Becton Dickinson, and Company, Molecular Devices LLC, Bruker Corporation, and Sartorius AG. Major players in the live cell imaging market are Leica Microsystems, Olympus Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc, GE Healthcare, Carl Zeiss Meditec AG, Becton Dickinson, and Company, Molecular Devices LLC, Bruker Corporation, and Sartorius AG.
Major players in the sample preparation market are Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, Illumina, Qiagen NV, PerkinElmer, F Hoffman La Roche, Tecan Group Ltd, Hamilton Company, and Norgen Biotek Corporation. Major players in the sample preparation market are Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, Illumina, Qiagen NV, PerkinElmer, F Hoffman La Roche, Tecan Group Ltd, Hamilton Company, and Norgen Biotek Corporation.
PerkinElmer with ticker code (PKI) now have 10 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 200 and 167 with the average target price sitting at 184. With the stocks previous close at 142.49 this indicates there is a potential upside of 29.1%. There is a 50 day moving average of 161.32 and the 200 day MA is 175.97. The company has a market cap of $18,116m. Company Website: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets="PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $23,394m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.